Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
I. Medical Department - Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Endocr Pathol. 2020 Jun;31(2):182-189. doi: 10.1007/s12022-020-09612-7.
Neuroendocrine neoplasms comprise a heterogeneous group of tumors, categorized into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) depending on tumor differentiation. NECs and high-grade NETs (G3) confer a poor prognosis, demanding novel treatment strategies such as immune checkpoint inhibition in tumors with microsatellite instability (MSI). To study any possible intratumoral heterogeneity of MSI, a tissue microarray (TMA) containing 199 NETs and 40 NECs was constructed to screen for MSI using immunohistochemistry (IHC) for the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. Four cases suspicious for MSI were identified. Validation of MSI by repeated IHC on large sections and polymerase chain reaction (PCR)-based analysis using the "Bethesda Panel" confirmed MSI in 3 cecal NECs. One pancreatic NET G3 with MSI-compatible TMA results was MMR intact on large section IHC and microsatellite stable (MSS). The remaining 235 tumors exhibited intact MMR. Protein loss of MLH1/PMS2 was found in two and MSH6 loss in one cancer with MSI. Large section IHC on all available tumor-containing tissue blocks in NECs with MSI did not identify aberrant tumor areas with intact MMR. Our data indicate that MSI is common in colorectal NECs (3 out of 10) but highly infrequent in neuroendocrine neoplasms from many other sites. The lack of intratumoral heterogeneity of MMR deficiency suggests early development of MSI during tumorigenesis in a subset of colorectal NECs and indicates that microsatellite status obtained from small biopsies may be representative for the entire cancer mass.
神经内分泌肿瘤包含一组异质性肿瘤,根据肿瘤分化程度分为神经内分泌肿瘤(NETs)和神经内分泌癌(NECs)。NECs 和高级别 NETs(G3)预后不良,需要新的治疗策略,如在具有微卫星不稳定(MSI)的肿瘤中使用免疫检查点抑制。为了研究 MSI 可能存在的肿瘤内异质性,构建了一个包含 199 个 NETs 和 40 个 NECs 的组织微阵列(TMA),通过免疫组化(IHC)检测错配修复(MMR)蛋白 MLH1、PMS2、MSH2 和 MSH6 来筛选 MSI。发现了 4 例疑似 MSI 的病例。通过对大切片进行重复 IHC 和基于聚合酶链反应(PCR)的“Bethesda 小组”分析验证 MSI,确认 3 例盲肠 NEC 存在 MSI。1 例具有 MSI 兼容 TMA 结果的胰腺 NET G3 在大切片 IHC 和微卫星稳定(MSS)上 MMR 完整。其余 235 例肿瘤显示完整的 MMR。在具有 MSI 的肿瘤中,2 例 MLH1/PMS2 蛋白丢失,1 例 MSH6 丢失。在所有具有 MSI 的 NEC 中,所有可用的包含肿瘤组织块的大切片 IHC 均未发现具有完整 MMR 的异常肿瘤区域。我们的数据表明,MSI 在结直肠 NEC(3/10)中很常见,但在许多其他部位的神经内分泌肿瘤中很少见。MMR 缺陷的肿瘤内异质性缺乏表明在结直肠 NEC 中 MSI 是在肿瘤发生的早期发展,并且表明从小活检获得的微卫星状态可能代表整个癌症质量。